Resources
BNET Resources
- sort by:
- Relevance
- Date
- Popularity
- SCOLR Pharma, Inc. and Dr. Reddy's Laboratories Enter into Collaboration and License Agreement
- BELLEVUE, Wash. -- SCOLR Pharma, Inc. (AMEX: DDD) today announced that it has entered into a collaboration and license agreement with Dr. Reddy's Laboratories (NYSE:RDY), an emerging global pharmaceutical company. The parties will pursue the development and commercialization of an undisclosed oral prescription drug with significant potential for the cardiopulmonary...
- Research articles 2007-10-23
- EXACT Sciences and NorDiag Announce International Collaboration and License Agreement for Colorectal Cancer
- MARLBOROUGH, Mass. & OSLO, Norway -- EXACT Sciences Corporation (NASDAQ: EXAS) and NorDiag ASA (OSE: NORD) announced today that they have entered into a collaboration and a non-exclusive license agreement to advance the development and commercialization of colorectal cancer CRC screening technologies outside the U.S. and Canada. Under the terms...
- Research articles 2007-06-05
- A&G Pharmaceutical and MedImmune Sign Collaboration and License Agreement for Oncology Research
- Business Editors/Health & Medical Writers
- Research articles 2002-04-24
- Geron Enters into a Collaboration and License Agreement with MERCK & CO., INC. for Cancer Vaccines Targeting Telomerase
- MENLO PARK, Calif. -- Geron Corporation (Nasdaq:GERN) announced today it has entered into a collaboration and license agreement with Merck & Co., Inc. (NYSE:MRK) to develop a cancer vaccine targeting telomerase utilizing Merck's expertise in vaccine technologies.
- Research articles 2005-07-18
- Gladstone Institutes and Merck & Co., Inc. Announce Major Research Collaboration and Exclusive License Agreement in Field of Apolipoprotein E
- Research Focuses on Treatment and Prevention of Alzheimer's Disease by Altering ApoE4-induced Neuronal Dysfunction
- Research articles 2006-11-02
- Panacea Pharmaceuticals, Inc. and MedImmune, Inc. Sign Collaboration and License Agreement to Discover, Develop, and Commercialize Cancer Therapeutics
- Business Editors/Health & Medical Writers
- Research articles 2002-04-19
- Agensys Signs Collaboration and License Agreement with Genentech
- SANTA MONICA, Calif. -- Agensys, Inc., a cancer biotechnology company, today announced an agreement with Genentech Inc. (NYSE:DNA) for the research, development and commercialization of therapeutic and diagnostic products to two of Agensys' proprietary cancer targets. The agreement provides Genentech with exclusive worldwide licenses under Agensys' patent rights for the...
- Research articles 2004-07-22
Additional Resources
- Nixon Peabody Represents Galenea Corp. in Collaboration and License Agreement with Otsuka Pharmaceutical Co., Ltd
- CAMBRIDGE, Mass. -- Galenea Corp., an emerging biotechnology company, has signed a research and development collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. to discover novel pharmaceuticals for the treatment of central nervous system CNS diseases, including schizophrenia and bipolar disorder. The parties' collaboration includes an equity investment in...
- Research articles 2005-02-17
- Merck & Co., Inc. and Cardiome Pharma Corp. sign a collaboration and license agreement for the development and commercialization of vernakalant, an investigational candidate for the treatment of atrial fibrillation.(INDUSTRIAL Briefs)
- Merck & Co., Inc. and Cardiome Pharma Corp. sign a collaboration and license agreement for the development and commercialization of vernakalant, an investigational candidate for the treatment of atrial fibrillation. The agreement provides Merck with exclusive global rights to the oral formulation of vernakalant...
- Research articles 2009-05-01
- MethylGene Announces Worldwide Research Collaboration and License Agreement With Otsuka Pharmaceutical Co. Ltd.
- MethylGene Inc. (TSX: MYG), today announced a worldwide research collaboration and license agreement with Otsuka Pharmaceutical Co. Ltd., a global pharmaceutical company, for the development of novel, small molecule, kinase inhibitors for the local delivery and treatment of ocular diseases, excluding cancer. MethylGene will be responsible for the design,...
- Research articles 2008-03-27
- MethylGene Announces Worldwide Research Collaboration and License Agreement With Otsuka Pharmaceutical Co. Ltd. - US$55 million potential deal value - Leverages oncology-focused kinase research capabilities into ocular diseases - Otsuka is a leading, glob
- MONTREAL, QUEBEC, Mar 27, 2008 Marketwire via COMTEX -- MethylGene Inc. (TSX:MYG), today announced a worldwide research collaboration and license agreement with Otsuka Pharmaceutical Co. Ltd., a global pharmaceutical company, for the development of novel, small molecule, kinase inhibitors for the local delivery and treatment of...
- Research articles 2008-03-27
- Ablynx Enters into a Research and License Agreement with Wyeth
- GHENT, Belgium -- Ablynx, the pioneer in the discovery and development of Nanobodies([R]), a novel class of antibody-derived therapeutic proteins, has announced that they have entered into an exclusive research collaboration and license agreement with Wyeth Pharmaceuticals, a division of Wyeth (NYSE:WYE), to discover, develop and commercialise Nanobodies([R]) directed at...
- Research articles 2006-11-06
- Biogen Idec and mondoBIOTECH Sign Collaboration and Licensing Agreement to Develop and Commercialize Aviptadil for Pulmonary Arterial Hypertension
- CAMBRIDGE, Mass., and Switzerland -- Biogen Idec (NASDAQ: BIIB) and mondoBIOTECH AG, a private Swiss biotechnology company, today announced the signing of an exclusive collaboration and license agreement for Biogen Idec to develop, manufacture and commercialize Aviptadil, a clinical compound for the treatment of Pulmonary Arterial Hypertension PAH.
- Research articles 2006-09-14
- Tundra Semiconductor and IBM Extend Technology Collaboration and License Pact
- Wireless News 12-02-2007 Tundra Semiconductor and IBM Extend Technology Collaboration and License Pact WIRELESS NEWS-December 2, 2007-Tundra Semiconductor and IBM Extend Technology Collaboration and License Pact C2007 10Meters - http://www.10meters.com Tundra Semiconductor has announced the extension...
- Research articles 2007-12-02
- Luminex Announces Development Collaboration and License Agreement with Major Healthcare and Research Organization
- AUSTIN, Texas & ROCHESTER, Minn. -- Luminex Corporation (Nasdaq: LMNX), the world leader in multiplexed solutions, and Mayo Clinic today announced that they have signed a development licensing agreement that enables Mayo to provide genetic and other testing services to patients using Luminex's xMAP[R] technology. The agreement contains collaboration and...
- Research articles 2007-11-27
- Merck & Co., Inc. and Cardiome Sign License Agreement for Vernakalant, an Investigational Drug for Treatment of Atrial Fibrillation
- WHITEHOUSE STATION, N.J. & VANCOUVER -- Merck & Co., Inc. and Cardiome Pharma Corp. (NASDAQ: CRME / TSX: COM) today announced a collaboration and license agreement for the development...
- Research articles 2009-04-08
- Wyeth Pharmaceuticals and Nautilus Biotech Announce Collaboration to Develop Hemophilia Therapies.
- PARIS, February 5 /PRNewswire/ -- Nautilus Biotech today announced the signing of a research collaboration and license agreement to discover and develop novel recombinant Factor IX proteins for hemophilia B with Wyeth Pharmaceuticals, a division PARIS, February 5 /PRNewswire/ -- ...
- Research articles 2007-02-05
- Addex Achieves First Milestone in Parkinson's Disease Collaboration With Merck & Co., Inc.
- Allosteric modulation company Addex Pharmaceuticals (SWISS: ADXN) announced today that the first preclinical milestone has been achieved in a recently announced exclusive collaboration and license agreement with Merck & Co., Inc. (through its affiliate Merck Sharp & Dohme Research Ltd). The collaboration is focused on developing an emerging class of...
- Research articles 2008-02-25
- Addex Achieves First Milestone in Parkinson's Disease Collaboration with Merck & Co., Inc.
- Allosteric modulation company Addex Pharmaceuticals (SWX: ADXN) announced today that the first preclinical milestone has been achieved in a recently announced exclusive collaboration and license agreement with Merck & Co., Inc. (through its affiliate Merck Sharp & Dohme...
- Research articles 2008-02-25
- Incyte's Collaboration with Novartis AG Presents Great Opportunity
- Zacks.com submits: Incyte Corporation INCY entered into a collaboration and license agreement with Novartis AG NVS regarding two of its pipeline candidates – INCB18424, an oral JAK1/JAK2 inhibitor and INCB28060, an oral cMET inhibitor. While the former is currently being studied in a phase III clinical trial for...
- External links 2009-12-01
- << Previous
- page 1 of 1
- Next >>
Presented by American Express